Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor by Prawitt,  D. et al.
Microdeletion of target sites for insulator protein
CTCF in a chromosome 11p15 imprinting center in
Beckwith–Wiedemann syndrome and Wilms’ tumor
Dirk Prawitt*†‡, Thorsten Enklaar*†, Barbara Ga¨rtner-Rupprecht*, Christian Spangenberg*, Monika Oswald*,
Ekkehart Lausch*, Peter Schmidtke*, Dirk Reutzel*, Stephan Fees*, Rob Lucito§, Maria Korzon¶, Izabela Brozek,
Janusz Limon, David E. Housman**, Jerry Pelletier††, and Bernhard Zabel*
*Children’s Hospital, University of Mainz, Langenbeckstrasse 1, D-55101 Mainz, Germany; §Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring
Harbor, NY 11724; ¶Departments of Pediatrics, Gastroenterology, and Oncology, and Departments of Biology and Genetics, Medical University of Gdansk,
80-822 Gdansk, Poland; **Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; and ††Department of Biochemistry
and McGill Cancer Center, McGill University, Montreal, QC, Canada H3G 1Y6
Contributed by David E. Housman, January 4, 2005
We have analyzed several cases of Beckwith–Wiedemann syndrome
(BWS) with Wilms’ tumor in a familial setting, which give insight into
the complex controls of imprinting and gene expression in the
chromosome 11p15 region. We describe a 2.2-kbp microdeletion in
the H19insulin-like growth factor 2 (IGF2)-imprinting center elim-
inating three target sites of the chromatin insulator protein CTCF
that we believe here is necessary, but not sufficient, to cause BWS
and Wilms’ tumor. Maternal inheritance of the deletion is associ-
ated with IGF2 loss of imprinting and up-regulation of IGF2 mRNA.
However, in at least one affected family member a second genetic
lesion (a duplication of maternal 11p15) was identified and accom-
panied by a further increase in IGF2 mRNA levels 35-fold higher
than control values. Our results suggest that the combined effects
of the H19IGF2-imprinting center microdeletion and 11p15 chro-
mosome duplication were necessary for manifestation of BWS.
insulin-like growth factor 2  H19  differentially methylated region
Genomic imprinting is an important component of the reg-ulation of human gene expression, and a number of genetic
diseases can be caused by errors in imprinting. The imprinting of
a gene is thought to be regulated by epigenetic modifications,
such as CpG methylation, which are coordinated by imprinting
centers (ICs). The mechanism of this regulation appears to be
complex but of potential importance in developing therapeutic
interventions for disorders caused by imprinting errors.
Beckwith–Wiedemann syndrome (BWS), a congenital over-
growth condition, in which 5% of children develop embryonal
tumors [predominantly Wilms’ tumor (WT)] is associated with
escape from epigenetic silencing [loss of imprinting (LOI)] of
genes on chromosome 11p15. The three most frequent findings
identified are (i) loss-of-function alterations in the CDKN1C
gene (reviewed in ref. 1), (ii) alterations affecting the tight
regulation of 11p15 gene expression [e.g., insulin-like growth
factor 2 (IGF2)-LOI], observed in cases with uniparental pater-
nal disomy (patUPD) (2), and (iii) alterations smaller than
patUPDs that cluster to two ICs implicated in the control of
epigenetically regulated genes in 11p15.5. The proximal IC is
termed IC2 or KvDMR1 [KvLQT1-associated differentially
methylated region (DMR) 1]. Hypomethylation of this sequence
mediates silencing of the KCNQ1 and CDKN1C genes by per-
mitting transcription of the antisense transcript KCNQ1OT1 (3,
4). The distal IC, IC1, is a DMR positioned between H19 and
IGF2. The expression of these two reciprocally imprinted genes
is dependent on the same enhancers located distal of H19 (5).
Access to these enhancers is regulated by binding of CTCF
(CCCTC-binding factor) to the unmethylated maternal IC1
allele, thus creating a functional chromatin boundary and block-
ing the interaction of IGF2 promoters and enhancers. IC1-
methylation (on the paternal chromosome) prevents CTCF
binding, thus allowing IGF2 expression (6, 7). Human IC1
contains seven CTCF target sites (CTSs) (Fig. 1). Methylation
aberrations of IC1 have been reported to occur in a graded
fashion, and pathologic conditions are associated with aberrant
methylation resulting in IGF2-LOI (8, 9) or H19-LOI (10).
Small deletions can give insight into the function of an
imprinted region and have been extremely informative in un-
derstanding Prader–Willi syndrome and Angelman syndrome,
where paternally or maternally transmitted 15q deletions, re-
spectively, lead to different complex syndromes (for review see
ref. 11). However, in BWS, small deletions that include chro-
mosomal ICs have not been identified until very recently. One
reportedmicrodeletion includes the entireKCNQ1OT1 gene and
when maternally inherited, causes BWS by silencing of CDKN1C
(12). Another microdeletion was described for IC1 (13). In two
families, each with one child that suffered from BWS, an
inherited 1.8-kbp microdeletion in theH19DMR eliminated two
CTSs. Maternal transmission of the deletion correlated with
hypermethylation of the H19 DMR, biallelic IGF2 expression,
H19 silencing, and the BWS phenotype.
We report on a microdeletion for chromosome 11p15 IC1 that
occurs in a familial setting in a sibship with three cases of BWS
andWT. We describe a 2.2-kbp microdeletion in theH19IGF2-
IC, eliminating three target sites of the chromatin insulator
protein CTCF, which we believe is necessary but not sufficient
to cause BWS and WT. Maternal inheritance of the deletion is
associated with IGF2-LOI and up-regulation of IGF2 mRNA.
However, in at least one affected family member, a second
genetic lesion, duplication of maternal 11p15, was identified,
which was absent in unaffected family members, suggesting that
the combined effects of the deletion and chromosome duplica-
tion were necessary for the BWS disease phenotype to manifest.
Materials and Methods
BWSWT Family Members. Informed written consent was obtained
from the adult individuals, and consent was obtained from
parents for minors. The ethical Review Board of Germany
approved all study protocols.
Allelotyping, 11p Marker Analysis, and Southern Blotting Analysis.
Genomic DNA was isolated from peripheral blood lymphocytes
by using the Wizard genomic DNA purification kit (Promega).
Abbreviations: BWS, Beckwith–Wiedemann syndrome; IC, imprinting center; LOI, loss of
imprinting; WT, Wilms’ tumor; DMR, differentially methylated region; IGF2, insulin-like
growth factor 2; CTS, CTCF target site; patUPD, uniparental paternal disomy; SNP, single-
nucleotide polymorphism.
†D.P. and T.E. contributed equally to this work.
‡To whom correspondence should be addressed: E-mail: prawitt@molgen.medizin.uni-
mainz.de.
© 2005 by The National Academy of Sciences of the USA
www.pnas.orgcgidoi10.1073pnas.0500037102 PNAS  March 15, 2005  vol. 102  no. 11  4085–4090
G
EN
ET
IC
S
Then 42 polymorphic microsatellite markers spanning the entire
short arm of chromosome 11 were PCR amplified and analyzed
with an ABI 310 capillary sequencing machine (Applied Bio-
systems). Southern analysis for the IC1 region was performed by
using 10 g of BglII-digested genomic DNA, hybridized with a
PCR-generated probe detecting the B7 repeat (primers were
B7F, 5-GGAGAACCAAGCATTAATGCG-3, and B7R, 5-
AGTCATGACCACTGCAGAAC-3). Genomic DNA of all
coding exons of WT1, CDKN1C, and CTCF were sequenced by
using an ABI PRISM 377 DNA analyzer (Applied Biosystems).
Primer sequences are available on request.
Bisulfite Sequencing. Two micrograms of genomic DNA from
peripheral blood lymphocytes were cleaved with TliI, BsiWI, and
BsmBI (New England Biolabs) overnight at 55°C, purified, and
treated with the CpGenome DNA modification kit according to
the manufacturer’s instructions (Invitrogen). Bisulfite-treated
DNA samples were PCR amplified as described (8). Purified
PCR products were cloned into a T-vector (Promega), and 16–20
independent clones per patient were sequenced.
FISH. IGF2 cosmid clone RPCI-11-46C8 (IGF2 genomic se-
quence GenBank accession no. AC132217.15) was nick trans-
lated with Cy3- or SpectrumGreen-dUTP according to the
manufacturer’s instructions (Roche). Metaphase spreads were
prepared from fibroblasts (14), and FISH was performed to-
gether with a CEP11-SpectrumGreen probe (Vysis, Downers
Grove, IL) as described (15). Posthybridization washes were
done at 71°C in 0.4 SSC and 0.3% Nonidet P-40 for 2 min, and
in 2 SSC and 0.1% Nonidet P-40 for 2 min. Images were
analyzed by using CYTOVISION 3.52 software (Applied Imaging,
San Jose, CA).
Quantitative Genomic PCR. Relative quantification by real-time
PCR was carried out by using a Roche LightCycler system and
SYBR Green mix (Roche) with 3.5 mM MgCl2 in 10-l reac-
tions. Cycling conditions were 95°C for 10 min, followed by up
to 50 cycles of 95°C (5 sec), 65°C (2 sec), and 72°C (3 sec).
Primers for amplification of IC1 (IC1 genomic sequence Gen-
Bank accession no. AF125183) with and without the microde-
letion were forward (0.6 M), 5-CGGTTGTAAGTGTG-
GACTCAA-3 or 5-TGGTTGTAGTTGTGGAATCGG-3,
respectively, and reverse (0.4 M), 5-CTGTGGATAATGC-
CCGACCT-3.
Quantitative RT-PCR of IGF2 Alleles. Total RNA (4 g), random
hexamer, and Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen) were used for cDNA production. Forward
primers for isoform-specific cDNA-PCR amplification were
IGF2-3F, 5-GGACAATCAGACGAATTCTCC-3 (isoform 3)
and IGF2-4F, 5-CTTCTCCTGTGAAAGAGACTTC-3 (iso-
form 4) and for isoform independent amplification IGF2-8F,
5-TCCTGGAGACGTACTGTGCTA-3. General reverse primer
was IGF2-9R, 5-CGGGGATGCATAAAGTATGAG-3.
Relative quantitative analysis was performed by using real-
time PCR with the cDNA samples prepared as described above.
Amplifications were done in 10- or 20-l reactions with the
SYBR Green mix (Roche), 3.5 mM MgCl2, and 0.6 M primers
(IGF2-3F, -4F, IGF2-7R: 5-CAGCAATGCAGCACGAGGC-
GAAGGC-3, IGF2-8F, -9R) with cycling conditions: 95°C for
10 min and up to 55 cycles of 95°C (4 sec), 64°C (7 sec), and 72°C
(40 or 10 sec for isoform-independent or isoform-specific am-
plification, respectively). cDNA concentrations were calculated
in respect to equal cDNA starting amounts relative to GAPDH
and pyruvate dehydrogenase amplifications.
Results
Chromosome 11 Genotyping of Familial BWS with WT. We analyzed
a large, three-generation family with three children affected by
BWS (Fig. 1A) presenting with the cardinal features of this
syndrome: overgrowth (90th to 95th percentile), macroglossia,
umbilical hernia, hepatomegaly, and WT. Microsatellite marker
analysis excluded patUPD for 11p in this family (data not
shown). A single maternal 11p15 haplotype was found to be
common to all affected (III.1, III.2, and III.5) and two unaf-
fected children (III.4 and III.8) (data not shown). This result
suggested that the genetic lesion responsible for BWS in this
family resides on the maternal chromosome bearing this haplo-
type. In addition, transmission of the same haplotype to both
affected and unaffected children suggests that at least one
Fig. 1. IC1 structure in the three-generation BWS family with WT. (A)
Pedigree of a large three-generation family with three children affected by
BWS and WT. *, Those individuals who inherited the same 11p15 maternal
haplotype, along with the IC1 deletion described in this report. The proband
(III.1) is indicated by an arrow. (B) Organization of the paternal and maternal
IC1 region in members of the BWSWT pedigree. The integral DMR status on
the paternal haplotype of individuals III.1, III.2, III.3, III.4, and III.5 is shown,
with B repeats represented by yellow boxes and A repeats denoted by gray
boxes. The locations of the CTCF-binding sites are denoted by small orange
hatches. The core CTS sequence is shown, with the blackened C or green T,
denoting a paternal or maternal single-nucleotide polymorphism (SNP), re-
spectively. Nucleotides specific for the B1 and B5 sequences are marked in red
and blue, respectively. The microdeletion generates a chimeric CTS sequence
derived from B1 and B5 repeats in the maternal haplotypes of III.1, III.2, III.4,
and III.5. The heterozygous nature of the deletion in III.1 was verified by
Southern blot analysis (Left).
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additional factor underlies the phenotypic variation among the
siblings who inherit this chromosome. The BWSWT individuals
in the sibship had an unaltered CDKN1C-coding sequence and
retained differential IC2 methylation, suggesting that the genetic
lesion responsible for their BWS might lie elsewhere in 11p15.5
(data not shown). We therefore undertook a detailed analysis of
the IC1 region.
Identification of a Microdeletion Within IC1. Initially we sought to
distinguish the maternal and paternal copies of the IC1 region.
We identified four SNPs in the B1A1 region (GenBank acces-
sion no. AF125183) of IC1, which were informative in the
sibship. Genotyping revealed that a single 11p15.5 haplotype had
been transmitted from the maternal grandmother to the mother
and to all three affected and two unaffected children. Direct
sequencing of the DMR from the inherited maternal haplotype
revealed that this haplotype carried a deletion in IC1 (Fig. 1B).
This deletion, generated by recombination between the B1 and
B5 repeats, eliminates one copy of repeat A and three and
one-half copies of repeat B, abolishing three CTSs (Fig. 1B).
Southern blot analysis confirmed the presence of the heterozy-
gous 2.2-kbp microdeletion (Fig. 1B). The deletion was not
present in the genomic DNA of the father, the maternal grand-
father, and two unaffected children, as well as in 100 control
chromosomes, excluding it as a common polymorphism (data not
shown).
We also assessed the methylation status of the B1, fused
B5B1, and A1 repeats of the IC1 region in four individuals of
this sibship. Sequencing of bisulfite-treated patient DNA indi-
cated that methylation was restricted to the paternal allele (Fig.
2). Because this pattern represents the normal epigenetic state
for the paternally transmitted allele, it further supports the view
that the genetic lesions in the maternally derived allele were
likely to be responsible for the BWS in this sibship.
Chromosomal Duplication of the Maternal IGF2 Locus. Our findings
implicate the microdeletion described above in the etiology of the
BWSWT phenotype. However, the microdeletion is inherited
from the maternal grandmother and mother without the occur-
rence of BWS and WT in either of these individuals and is also
transmitted to one of the siblings in the third generation without
BWS (III.4) (Fig. 1A). We considered the possibility that an
additional genetic event was necessary to manifest the symptoms of
BWS in this sibship. We were able to obtain primary fibroblast cell
cultures and primary lymphocytes from two of the siblings, one
affected and the other unaffected (III.1 and III.4), both of whom
had inherited the same maternal 11p haplotype containing the IC1
microdeletion. Karyotypic analysis revealed an additional lesion in
the affected sibling. High-resolution GTG banding of metaphase
chromosome spreads showed a prolonged 11p15 subtelomeric
region on one chromosome 11 of the proband. This finding was not
present on either chromosome 11 of the healthy sibling (Fig. 3A).
FISH analysis was therefore carried out to examine the DNA
sequences included in the duplication. A genomic probe for IGF2
detected a duplication of the distal part of 11p in fibroblasts (Fig.
3B). The presence of the duplication was also apparent when a
genomic real-time PCR quantitation assay was used. The presence
of the IC1 microdeletion enabled discrimination between the
maternal and paternal 11p15.5 copies in this assay, leading to results
consistent with a partial trisomy of 11p15 with a 2:1
(maternal:paternal) ratio (Fig. 3C). The occurrence of the distal
11p15 duplication in III-1 suggested that this genomic alteration
might account for the BWS of all three affected siblings. Were this
the case, the most likely mechanism that would account for the
occurrence of BWS in all three affected siblings would be maternal
gonadal mosaicism.
The IC1 Microdeletion Is Associated with IGF2 Overexpression. To
determine whether the genomic alterations affect transcription
of the neighboring IGF2 gene, we examined IGF2 mRNA levels
in the established fibroblasts. This analysis revealed a significant
up-regulation (5-fold compared with a normal fibroblast con-
trol) of the IGF2 transcript in the unaffected sibling (III.4).
However, the increase in IGF2 mRNA levels in the fibroblasts
Fig. 2. Methylation status of IC1 in children III.1, III.2, III.3, and III.4. Allele-specific methylation was analyzed by bisulfite sequencing of IC1 fragments, including
the core CTS in the B1 and B5B1 repeats (boxed). Paternal and maternal clones, identified by four SNPs (CTAT and TAGG), are grouped. F, methylated CpGs;
E, transformed unmethylated CpGs. Allele-specific paternal methylation was detected for the complete B1, as well as the fused B5B1 sequences, of all four DNA
samples.
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derived from the proband was considerably higher than in the
unaffected sibling: a total of 35-fold higher than in the normal
fibroblast control (Fig. 3D). IGF2 is transcribed from four
alternative promoters (P1–P4), generating mRNA isoforms dif-
fering in their 5 untranslated regions, with P3 and P4 respon-
sible for the majority of transcripts in most tissues. Although
transcripts from promoter P1 normally are expressed bialleli-
cally, promoters P2, P3, and P4 are maternally silent (16). Splice
version-specific real-time cDNA amplification revealed that
IGF2 overexpression in the fibroblasts was primarily the conse-
quence of enhanced usage of the P4 promoter, and in the case
of the fibroblasts from the affected child, to a lesser extent, of the
P3 promoter. We found the maternal and paternal IGF2 alleles
to contribute almost equally to expression of IGF2 in the
fibroblast from the unaffected child, whereas expression of IGF2
in fibroblasts from the BWS child was predominantly (83%) of
maternal origin (Fig. 3D).
Discussion
A key feature of the BWSWT family characterized herein is
that the maternal IGF2 copy appears to have been ‘‘paternal-
ized’’ by the IC1 microdeletion, leading to activation of the
normally silent maternal IGF2 allele. In general, BWS cases with
partial chromosome 11 duplications are of paternal origin
(patUPD), whereas duplication of maternal 11p15 is associated
with growth retardation, but not with BWS (17). The occurrence
of the microdeletion thus gives some insight into the control
mechanisms that regulate imprinting through IC1 (Fig. 4).
Although we found no methylation changes associated with the
IC1 microdeletion, deletion of the three CTSs results in loss of
insulation by CTCF on the maternal allele (schematically rep-
resented in Fig. 4). An additional structural difference in the
deleted allele that might also contribute to the loss of CTCF
insulation is the hybrid B5B1 sequence, which differs from the
normal B1 sequence at its 5 end (Fig. 4).
A number of previous studies have addressed the relationship
of IC1 to expression levels of IGF2 and H19. Takai and
coworkers (10) have suggested that methylationdemethylation
of the wrong IC1-CTS could adversely affect expression of either
IGF2 orH19 and that only B1 is differentially methylated and all
other B elements are hypermethylated on both alleles (10).
Methylation aberrations in the B1-CTS have been described for
WT (8), osteosarcoma (18), and colorectal (19) and bladder
cancer (10), which argue for a central role of the A1B1-B4
cluster in regulating IC1 function. Cui and coworkers (9, 20)
found differential methylation in the A2B5-B7 repeat cluster
(affecting the CTS in B7) in addition to the A1B1-B4 cluster as
well as B7 hypomethylation associated with colorectal cancer.
An IC with functional properties similar to the human IC1 has
been demonstrated in the mouse. The mouse IC1 contains four
CpG-rich CTS but has significant architectural differences from
the human IC1. Recent findings from Fedoriw and coworkers
(21) indicate that the murine CTCF can protect the H19 DMR
from de novo methylation during oocyte growth and is required
for normal preimplantation development. Reduced CTCF levels
result in hypermethylation of the CTS. A similar observation was
made when a deletion abolished a dyad-Oct-binding sequence,
resulting in a maternal IC1 methylation and subsequent LOI of
IGF2 (22). Because the murine IC1 region has a different
architecture compared with the human IC1, the function of the
putative human dyad-Oct-binding sequence in A2 still remains
to be determined. Dyad-Oct binding in human A1 and A2 may
protect the two clusters of CTS from regional hypermethylation.
The microdeletion described in the BWS patients in the present
study erases three CTSs (CTS3, CTS4, and CTS5 in repeats B5,
B3, and B2) and a putative dyad-Oct-binding sequence in A2.
Fusion of the B1B5 repeats generates a CTS, similar in
sequence to the original B5 repeat, which is differentially
methylated, like the original B1 repeat. Dyad-Oct-binding in A1
therefore seems to work properly in maintaining differential
methylation in the neighboring CTS, although the deletion of the
putative dyad-Oct-binding sequence in A2 might result in hy-
permethylation of the B6 and B7 repeats. The observed activa-
tion of the maternal IGF2 locus without hypermethylation of
CTS6 argues for a pivotal role of additional IC1-CTS in gener-
ating a functional CTCF block. Although the deletion described
by Sparago et al. (13) is smaller and encompasses fewer CTS than
our familial BWS case, they find that the retained fourth and
Fig. 3. Chromosome analysis, genomic quantitation of IC1 alleles, and quantitative RT-PCR analysis of allelic IGF2 expression. (A) Metaphase spreads of primary
fibroblasts from an affected individual (III.1) and unaffected individual (III.4) were analyzed. High-resolution GTG banding revealed a prolonged 11p15
subtelomeric region (black arrow) on one chromosome 11 of the proband. (B) FISH analysis with a genomic probe for IGF2 shows two signals on one chromosome
11 of the proband (yellow arrow), indicating a duplication of distal 11p. (Inset) An enlarged view of 11p to illustrate the duplication (yellow arrow). (C)
Quantitation of IGF2 gene dosage by using real-time PCR quantification. (D) Quantitative RT-PCR analysis, haplotype-specific expression, and promoter usage
of the IGF2 gene. The relative IGF2mRNA amounts are represented by horizontal bars, with colored segments denoting contribution of the parental haplotypes.
As well, the relative contribution to IGF2 expression by the P3 or P4 promoters is indicated by darker and lighter shading, respectively. Allelic contribution to
expression levels was determined by sequencing cloned transcripts of all individuals heterozygous for a SNP in IGF2 exon 9.
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sixth CTS (in B3 and B1) are hypermethylated. For the murine
IC, Kanduri and coworkers (23) demonstrated that nucleosome
positioning sites optimize the fidelity of the interaction of CTCF
with its target sites in the H19 DMR. Therefore alteration of
CTS6 methylation might reflect differences in nucleosome po-
sitioning with signals in the retained repeats B5–B7 because a set
of strong nucleosome positioning sites have been described for
this part of the H19 DMR (24).
The impact on BWS and WTs may be thought of in terms of
the effects of the IC microdeletion and 11p15 duplication on
IGF2 expression levels (Fig. 4). Transgenic mice that overexpress
Igf2 develop features of BWS, including prenatal and neonatal
overgrowth, organomegaly, and macroglossia. The overgrowth
phenotype is dependent on the Igf2 mRNA level. Although a
2-fold increase in murine Igf2 dose is sufficient to generate some
of the somatic overgrowth features of BWS (25), biallelic IGF2
expression in humans does not necessarily give identical results
(26). In mice a combination of two events, inactivation ofCdkn1c
and LOI of Igf2 (resembling the patUPD situation in BWS
patients) is necessary to produce a BWS-like phenotype (27).
Additional arguments in favor of IGF2 as a central player in
BWSWT pathogenesis come from studies of sporadic BWS
cases (28) and 40–60% of WTs (29), where biallelic expression
of IGF2 is observed. A variety of other pediatric tumors,
including the BWS-associated rhabdomyosarcoma and neuro-
blastoma (reviewed in ref. 30), also show IGF2 overexpression.
Finally, the enhanced IGF2 levels reported in cases of congenital
fibrosarcoma and congenital mesoblastic nephroma are of spe-
cial interest, because molecular studies implicate the presence of
an intact IGF signaling axis in malignant transformation (31).
However, loss of imprinting alone does not necessarily raise
IGF2 levels sufficiently to cause BWS. LOI of IGF2 without
pathologic effects has in fact been reported in peripheral blood
leukocytes in 10% of the normal population (26). In the case
of the familial BWS described here, LOI of IGF2 leads to
enhanced IGF2mRNA levels in the fibroblasts of the unaffected
child with the IC1 microdeletion, yet this LOI does not result in
BWS. The differences in phenotype between siblings with and
without 11p15 duplication are consistent with a threshold model
in which IGF2 expression levels that exceed a threshold are
critical in the etiology of BWS and its associated tumors. The IC1
deletion, according to this model, would drive pathogenesis as a
first hit by influencing the expression level of IGF2 (Fig. 4).
Increased IGF2 levels may contribute to the BWS phenotype and
predispose to WTs by leading to unscheduled stimulation of the
insulin receptor. This in turn would activate the phosphatidyl-
inositol 3-kinaseAktmTOR pathway, a signal transduction
cascade implicated in regulating cell size and proliferation. The
further understanding of the complex pattern of control exerted
through the chromosome 11p15 ICs in BWS should be helpful in
ultimately designing therapeutic intervention for this disorder
and its associated tumors.
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